World Health Organization

Influenza A(H1N1)pdm09 egg-derived[1] candidate vaccine viruses for development and production of vaccines for use in the 2022-2023 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

25 February 2022

Candidate vaccine viruses (CVVs) (antigenically like A/Victoria/2570/2019 (Egg derived) - Accession number (GISAID): EPI_ISL_417210

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Indiana/02/2020	Wild type virus			WHO CCs
	X-349	Classical	NYMC	NYMC, USA NIID, Japan NIBSC, UK
	X-349A	Classical	NYMC	NYMC, USA NIID, Japan NIBSC, UK
A/Victoria/2570/2019	Wild type virus			WHO CCs and ERLs
	IVR-215	classical	Seqirus	
A/Victoria/3/2020	Wild type virus			WHO CCs and ERLs
	IVR-216	classical	Seqirus	
A/Victoria/1/2020	Wild type virus			WHO CCs and ERLs
	IVR-217	classical	Seqirus	
Not applicable (synthetic)	IDCDC-RG70A	reverse genetic	CDC	CDC, USA

引用元：WHOウェブサイト

https://www.who.int/publications/m/item/1.-a(h1n1)pdm09---egg-derived---northern-hemisphere-2022-2023

World Health Organization

Influenza A(H3N2) egg-derived [1] candidate vaccine viruses for development and production of vaccines for use in the 2022-2023 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

25 February 2022

Candidate vaccine viruses (antigenically like A/Darwin/9/2021 (egg derived) – Accession number (GISAID): EPI_ISL_2233240

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Darwin/9/2021	Wild type virus			WHO CCs NIBSC, UK
	NYMC X-369A	Classical	NYMC	WHO CCs and ERLs NYMC, USA
	CBER-47A		CBER/FDA	CBER/FDA, USA
	CBER-47B			
	SAN-010		Sanofi	Sanofi, USA NIID, Japan
	NIB-126		NIBSC	NIBSC, UK
	IVR-228		Seqirus	WHO CCs NIBSC, UK
A/Darwin/6/2021	Wild type virus			WHO CCs NIBSC, UK
	NYMC X-367A	Classical	NYMC	WHO CCs and ERLs NYMC, USA
	NIB-127		NIBSC	NIBSC, UK NIID, Japan
	IVR-227		Seqirus	WHO CCs NIBSC, UK
A/Michigan/173/2020	Wild type virus			WHO CCs and ERLs

引用元：WHOウェブサイト

https://www.who.int/publications/m/item/3.-a(h3n2)---egg-derived---northern-hemisphere-2022-2023

World Health Organization

Influenza B Victoria lineage egg-derived[1] candidate vaccine viruses for development and production of vaccines for use in the 2022-2023 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

25 February 2022

Candidate vaccine viruses (antigenically like B/Austria/1359417/2021 (egg derived) - Accession number (GISAID): EPI_ISL_1519459

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Austria/1359417/2021	Wild type virus			WHO CCs NIBSC, UK
	BVR-26	Classical	Seqirus	NIBSC, UK VIDRL, Australia NIID, Japan
B/Michigan/01/2021	Wild type virus			CDC, USA NIBSC, UK NIID, Japan
B/Singapore/WUH4618/2021	Wild type virus			WHO CCs and ERLs
B/Guangdong-Zhenjiang/1516/2021	Wild type virus			WHO CCs and ERLs
	CNIC-2107A	Classical	CCDC, China	WHO CCs and ERLs

引用元：WHOウェブサイト

https://www.who.int/publications/m/item/7.-influenza-b-victoria-lineage---egg-derived---northern-hemisphere-2022-2023

World Health Organization

Influenza B Yamagata lineage egg-derived[1] candidate vaccine viruses for development and production of vaccines for use in the 2022-2023 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

25 February 2022

Candidate vaccine viruses (antigenically like B/Phuket/3073/2013 (egg derived) - Accession number (GISAID): EPI_ISL_168822

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Phuket/3073/2013	Wild type virus			WHO CCs NIBSC, UK
	BVR-1B	Classical	Seqirus	VIDRL, Australia
B/California/12/2015		Wild type virus		CDC, USA
	BX-59A	Classical	NYMC	NIBSC, UK NYMC, USA
	BX-59B			NIBSC, UK NYMC, USA
B/Brisbane/9/2014	Wild type virus			WHO CCs NIBSC, UK
B/Utah/09/2014	Wild type virus			CDC, USA NIBSC, UK
B/Arizona/10/2015	BX-63	Classical	NYMC	NIBSC, UK NYMC, USA
	BX-63A			NIBSC, UK NYMC, USA
B/Hong Kong/3417/2014	Wild type virus			NYMC, USA
	BX-57	Classical	NYMC	NIBSC, UK NYMC, USA

引用元：WHOウェブサイト

https://www.who.int/publications/m/item/5.-influenza-b-yamagata-lineage---egg-derived---northern-hemisphere-2022-2023